MRK Merck Earnings and EPS analysis

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 49

EPS in 2026 (TTM): $1

Last Report Period Date: Sep 30, 2026

Currently, MRK's 12-month EPS stands at $1, according to the most recent financial reports. Merck's earnings per share in 2025 was reported at $7.3, marking a rise from $6.76 in 2024. MRK recorded an EPS of $2.05 for the quarterly period ending on Sep 30, 2026.

MRK earnings history

Historical annual and quarterly earnings per share (EPS) data for Merck
EPS (TTM)
$1
EPS Growth YoY (Quarterly)
-11.6%
EPS (Quarterly)
$2.05
EPS Growth (Quarterly)
479.6%

In 2025, Merck's earnings per share was $7.3, a rise of 8% from $6.76 in 2024. The quarterly earnings per share for the period ending Sep 30, 2026, was $2.05, showing a 11.6% decline compared to the same quarter last year. The trailing twelve months EPS for MRK is $1 as of September 2026. Merck's full-year EPS for 2024 was $6.76, a 4,728.6% rise compared to the previous year.

MRK EPS vs price chart

MRK EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-11.6%
EPS growth YoY
8%
EPS growth 3Y avg
8.4%
EPS growth 5Y avg
21.2%

Merck has recorded a decline in earnings per share of 11.6% in the past 12 months (YoY, quarterly). During the past three years, MRK registered an average yearly EPS growth of 8.4%. Merck had an average annual EPS growth of 21.2% in the last five years. Over the last decade, MRK had an average annual earnings per share growth of 16.5%.

MRK Earnings Waterfall

Breakdown of revenue, profit and net income for Merck

MRK Earnings vs Peers

What are the earnings of MRK compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol-Myers Squibb Company 13.85 178.7% 5.3% N/A
AMGN AMGEN Inc 26.92 88.1% 5.6% 2.9%
NVS Novartis AG 30.51 21.8% 31.2% 15.2%
ABT Abbott Laboratories 39.79 -51.4% -1.8% 8.2%
PFE Pfizer Inc 40.86 -3.5% -37.4% -3.7%
JNJ Johnson & Johnson 42.62 90.6% 17.7% 14.8%
LLY Lilly(Eli) & Company 46.57 95.6% 49.2% 27.5%
TEVA Teva- Pharmaceutical Industries Ltd 97.22 184.8% N/A N/A
MRK Merck & Co Inc 147.68 8% 8.4% 21.2%

All data is based on quarterly TTM periods, unless otherwise specified.